Selective Sentinel Lymphadenectomy for Human Solid Cancer

  • Stanley P. L. Leong
  • Yuko Kitagawa
  • Masaki Kitajima

Part of the Cancer Treatment and Research book series (CTAR, volume 127)

Table of contents

  1. Front Matter
    Pages i-xxiii
  2. Roger F. Uren, Robert B. Howman-Giles, David Chung, John F. Thompson
    Pages 15-38
  3. Charles E. Cox, Elizabeth S. Weinberg, Ben Furman, Laura B. White, Jayesh Patel, Daniel C. Dickson et al.
    Pages 77-104
  4. Sukamal Saha, Adrian G. Dan, Carsten T. Viehl, Markus Zuber, David Wiese
    Pages 105-122
  5. Yuko Kitagawa, Hirofumi Fujii, Makio Mukai, Atsushi Kubo, Masaki Kitajima
    Pages 123-139
  6. Michael J. Liptay
    Pages 141-148
  7. Alistair J. Cochran, Alice Roberts, Duan-Ren Wen, Rong-Rong Huang, Eijun Itakura, Frank Luo et al.
    Pages 207-220
  8. Hiroya Takeuchi, Robert A. Wascher, Christine Kuo, Roderick R. Turner, Dave S.B. Hoon
    Pages 221-252
  9. John F. Thompson, Roger F. Uren, Richard A. Scolyer, Jonathan R. Stretch
    Pages 269-287
  10. Back Matter
    Pages 289-297

About this book


Lymph node (LN) status is the most important prognostic indicator for the clinical outcome of patients in human solid cancer. Recent developments in sentinel lymph node (SLN) concept and technology have resulted in the application of this revolutionary approach to determine if cancer has metastasized. The underlying thesis in solid cancer biology is that metastasis generally starts in an orderly progression, often spreading through the lymphatic channels to the SLN. Thus, the logical approach is to harvest that specific SLN for thorough analysis.

The most exciting possibility of selective sentinel lymphadenectomy (SSL) is that it will lead to early diagnosis of micrometastasis in regional LNs. Early diagnosis makes it useful as a clinical staging procedure, and opens up new opportunities to study micrometastasis and its evolution within the SLNs.

New molecular and genetic tools may be used to dissect the mechanisms of lymphatic and hemotogenous routes of metastasis. If such mechanisms can be understood, new therapeutic advances may be developed to prevent the process of micrometastasis.


Minimally invasive surgery associated with reduced morbidity has transformed the management of cancer patients. Sentinel lymphadenectomy for staging and treatment of solid tumors is now standard of care in many settings. In this text, distinguished investigators review the technical aspects and clinical considerations related to this procedure.

Steven T. Rosen, M.D.
Series Editor


Staging breast cancer cancer cancer treatment carcinoma cell clinical trial gastric cancer melanoma metastasis tumor

Editors and affiliations

  • Stanley P. L. Leong
    • 1
  • Yuko Kitagawa
    • 2
  • Masaki Kitajima
    • 2
  1. 1.Department of SurgeryUniversity of California, Medical Center at Mount ZionSan Francisco
  2. 2.Department of SurgeryKeio University, School of MedicineTokyoJapan

Bibliographic information

  • DOI
  • Copyright Information Springer US 2005
  • Publisher Name Springer, Boston, MA
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-0-387-23603-2
  • Online ISBN 978-0-387-23604-9
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site